[A22-56] Sotrovimab (COVID-19, without supplemental oxygen, increased risk of severe disease) - Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2022
Project no.:
A22-56
Commission:
Commission awarded on 13.05.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults and adolescents aged 12 years and over and weighing at least 40 kg with COVID-19 who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19
- Patients ≥ 18 years: hint of a considerable added benefit
- Patients ≥ 12 to < 18 years: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.